Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Julien Mazières, Alexander Edward Dela Cruz Drilon, Amélie Lusque et al. · Annals of Oncology · 2019
Cited by 1,354 works. doi:10.1093/annonc/mdz167 Open-access PDF
Authors
- Julien Mazières
- Alexander Edward Dela Cruz Drilon
- Amélie Lusque
- Laurent Mhanna
- Alexis Benjamin Cortot
- Laura Mezquita
- Alesha A. Thai
- Céline Mascaux
- S. Couraud
- Rémi Veillon
- Michel M. van den Heuvel
- Joel W. Neal
- Nir Peled
- Martin Früh
- Terry L. Ng
- Valérie Gounant
- Sanjay Popat
- Joachim Diebold
- Joshua K. Sabari
- Viola Weijia Zhu
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis